Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| PA-20-190 | Other Identifier | NIH |
Not provided
Not provided
Not provided
Did not receive funding as anticipated.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institutes of Health (NIH) | NIH |
Not provided
Not provided
Not provided
Not provided
This study will demonstrate the beneficial effects of ketone bodies in type 1 diabetes (T1D) patients and will have significant translational applications to prevent serious metabolic conditions such as T1D induced diabetic cardiomyopathy (DCM).
T1D remains the primary cause of DCM. The long-term goal is to understand the mechanism of T1D leading to DCM. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in degrading the low-density lipoprotein receptors (LDLRs) and that increases the circulating LDL cholesterol (LDL-C). Further, PCSK9 increases duringT1D and that, in turn, decreases mitochondrial bioenergetics, transcription factor- mitochondrial (TFAM), and the mitochondrial numbers thus creates an oxidative stress. These changes lead to oxidation of high-density lipoprotein paraoxonase-1 (HDL-Pon1). Because Pon1 hydrolyzes homocysteine (Hcy), the oxidized Pon1 thus causes accumulation of Hcy (i.e. hyperhomocysteinemia; HHcy). Also, the 'metabolic memory' is associated with epigenetic modification (methylation) of genes encoding proteins such as thioredoxin interacting protein (TXNIP). Since methylation/epigenetics inhibits genes, this phenomenon generates even more amounts of Hcy. Investigators have shown that HHcy decreases G-protein coupled receptor (GPCR) Gαs subunit, protein kinase-B (AKT), focal adhesion kinase (FAK) but increases calpain-1, inflammasome and oxidative stress. The central hypothesis is that an increase in PCSK9 causes oxidative stress and decreases TXNIP thus causing oxidation of HDL-Pon1 and subsequent accumulation of Hcy. These alterations lead to decrease in Gαs, AKT, FAK and concomitant increase in PCSK9 and calpain-1 causing metabolic, diastolic, and systolic cardiac dysfunction. Treatment with ketone bodies (the food for mitochondria) will mitigate these changes.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control subjects (non-diabetic). | Other | Control subjects (non-diabetic): 10 subjects: No intervention (placebo). 10 subjects: Intervention (probiotic) |
|
| Diabetic Subjects | Other | Diabetic subjects: 10 subjects: No intervention (placebo). 10 subjects: Intervention (probiotic) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Probiotic | Dietary Supplement | Oral administration of a probiotic |
|
| Measure | Description | Time Frame |
|---|---|---|
| Primary Outcome Measure-I | Levels of glucose in blood and urine | 4 years |
| Primary Outcome Measure-II | Cardiac function evaluation by electrocardiogram | 4 years |
| Measure | Description | Time Frame |
|---|---|---|
| Secondary Outcome Measure-I | Biochemical estimation of biomarkers from blood samples | 4 years |
Not provided
Inclusion Criteria:
-Diabetic subjects with high blood glucose levels
Exclusion Criteria:
- Comorbidities affecting glucose levels and cardiac function
Both male and female representing race/ethnicity
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mahavir Singh, DVM, MS, PhD | University of Louisville School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Louisville School of Medicine | Louisville | Kentucky | 40202 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30832381 | Result | Mishra SP, Wang S, Nagpal R, Miller B, Singh R, Taraphder S, Yadav H. Probiotics and Prebiotics for the Amelioration of Type 1 Diabetes: Present and Future Perspectives. Microorganisms. 2019 Mar 2;7(3):67. doi: 10.3390/microorganisms7030067. | |
| 35299968 | Result | Wang CH, Yen HR, Lu WL, Ho HH, Lin WY, Kuo YW, Huang YY, Tsai SY, Lin HC. Adjuvant Probiotics of Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 Attenuate Glycemic Levels and Inflammatory Cytokines in Patients With Type 1 Diabetes Mellitus. Front Endocrinol (Lausanne). 2022 Mar 1;13:754401. doi: 10.3389/fendo.2022.754401. eCollection 2022. |
Not provided
Not provided
Outcomes of the probiotic intervention in diabetic patients for the prevention of cardiomyopathy.
As soon as the data is collected, and fully analyzed.
Via personal meetings, national and international conferences.
Not provided
Not provided
| ID | Term |
|---|---|
| D058065 | Diabetic Cardiomyopathies |
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D009202 | Cardiomyopathies |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D048909 | Diabetes Complications |
Not provided
Not provided
| ID | Term |
|---|---|
| D019936 | Probiotics |
| ID | Term |
|---|---|
| D019587 | Dietary Supplements |
| D005502 | Food |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
Not provided
Not provided
Diabetic, and non-diabetic subjects.
Not provided
Not provided
Not provided
Not provided
| D003920 |
| Diabetes Mellitus |
| D004700 | Endocrine System Diseases |
| D019602 |
| Food and Beverages |